As Democrats in the US Congress work to move legislation empowering the Health and Human Services Department to negotiate drug prices directly with manufacturers, the Center For American Progress releases an analysis on which drugs would be targeted by House bill HR 3 and how much prices could be reduced.
Implementation of the federal government price negotiation program described in House legislation HR 3 could save Medicare Part D and beneficiaries $6,000 to $8,000 per month off the net prices of three high-cost oncology drugs: Celgene Corporation’s Revlimid, Pfizer Inc.’s Ibrance and Astellas Pharma, Inc.’s Xtandi, according to a new analysis from the Center for American Progress.
The analysis also projects that negotiation would lower the monthly net prices of AbbVie Inc.’s Humira Pen and
Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
There is a place for using external reference pricing to set prices of advanced therapies, but any such mechanism must take into account the specificities of the Brazilian market and health system.
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
Pink Sheet reporter and editors discuss the potential impact of the Most-Favored Nation drug pricing proposal on Europe, the United States, as well as the pharmaceutical industry.
